Biotechnology company Imugene (ASX:IMU) said a bile tract cancer patient in its phase 1 metastatic advanced solid tumors trial for Vaxinia, a treatment candidate for bile tract cancer, remained in complete response, surpassing over two years in remission, according to a Tuesday filing with the Australian bourse.

Meanwhile, the trial's bile tract cancer expansion phase cleared its first group, with the three patients experiencing no dose-limiting toxicities, and is now open for enrollment of up to 10 patients, the filing said.

The company also secured a patent extension to 2040 from the US Patent and Trademark Office for patent application number 16/324,541, protecting its oncolytic virotherapy CF33, including Vaxinia and CHECKVacc, according to the filing.

Imugene shares fell past 2% in morning trade Wednesday.

Price (AUD): $0.05, Change: $-0.001, Percent Change: -2.13%